ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026
Natural history of self-reported symptoms following SARS-CoV-2 infection: A target trial emulation in a prospective community-recruited cohort.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal trajectories of long COVID among hospitalized patients with omicron infection in Changzhi, China.Frontiers in medicine · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundUsing a prospective, community-recruited cohort with data on background symptom prevalence and repeated longitudinal symptom assessments, we estimated postinfection risks of long Coronavirus disease (COVID) symptoms compared with contemporaneous uninfected controls.
methodsWe analyzed the CHASING COVID Cohort, a US longitudinal study with surveys and serology (March 2020-December 2023). Infection status (January 2021-December 2022) was determined from self-reported PCR/antigen results, serology, or Council of State and Territorial Epidemiologists probable criteria. We emulated 24 monthly target trials comparing individuals newly infected at time zero with those remaining uninfected. Outcomes were new-onset long-COVID symptoms not reported preinfection, assessed overall and within three clusters (neurological, autonomic, and exercise intolerance) at 4-8 and 9-12 months postinfection. Inverse probability of treatment and censoring weights adjusted for confounding and informative loss to follow-up.
resultsThe analysis included 1055 infected and 52,310 uninfected person-trials. At 4-8 months, the adjusted risk of any long-COVID symptom was 22.6% (95% CI, 20.5-24.8) among infected vs 11.3% (11.1-11.5) among uninfected (adjusted risk difference [aRD], 11.3% [9.2-13.5]; adjusted risk ratio [aRR], 2.01 [1.81-2.20]). At 9-12 months, risks were 19.2% (17.0-21.3) vs 12.4% (12.2-12.7) (aRD, 6.7% [4.6-8.9]; aRR, 1.54 [1.37-1.72]). Across all three clusters, infected participants had consistently higher risks at both intervals.
conclusionsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was associated with an elevated risk of new-onset long-COVID symptoms persisting up to 12 months. Using a national community-recruited cohort, contemporaneous uninfected controls, and target-trial emulation clarifies the burden attributable to infection and supports ongoing surveillance and targeted prevention and care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.